Oliver Thiel is a highly accomplished professional with a diverse background in organic chemistry and business management. He earned a Bachelor's in Economics and a Master's in Business Administration from Fernuniversität in Hagen, Germany, while also studying Organic Chemistry at Stanford University and the Technical University of Munich.

Thiel's professional career spans over two decades at Amgen, where he has held various roles in research and development, process development, technology business operations, and strategy. He currently serves as the Executive Director of Process Development, Drug Substance Technologies Pivotal, and Commercial Synthetics.

Thiel's expertise includes drug development, process manufacturing, and technology operations. He has contributed to the commercial success of several drug products, including Enbrel, Neulasta, and Prolia. He is also experienced in project management, strategic planning, and team leadership.

In addition to his work at Amgen, Thiel has published several peer-reviewed articles in scientific journals and is an inventor on multiple patents. He is a member of the American Chemical Society and the German Chemical Society.